BMJ open · 2014
Extended-release nifedipine and the risk of intestinal obstruction: a population-based study.
Сравнительное исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Juurlink David N, Hellings Chelsea, Gomes Tara, Huang Anjie, Paterson J Michael, Urbach David R, Mamdani Muhammad M, Canadian Drug Safety and Effectiveness Research Network (CDSERN)
Аннотация
OBJECTIVES: To examine the risk of bowel obstruction in older adults during treatment with extended-release nifedipine compared with patients treated with amlodipine.
DESIGN: Retrospective cohort study using multiple linked healthcare databases.
SETTING: Ontario, Canada from 1 April 1997 to 31 December 2010.
PARTICIPANTS: We identified patients aged 66 years and older who started treatment with Adalat XL, an extended-release nifedipine product employing a tablet delivery system associated with mechanical bowel obstruction. For comparison, we studied patients receiving amlodipine, a long-acting calcium channel blocker that does not utilise the same delivery system and has not been implicated as a cause of bowel obstruction. Propensity score matching was used to ensure similarity of patients receiving the two drugs.
PRIMARY OUTCOME MEASURE: HR for the association between extended-release nifedipine relative to amlodipine and hospitalisation for bowel obstruction during therapy.
RESULTS: Over the 13-year study period, we identified 103 657 patients treated with extended-release nifedipine and 204 733 patients treated with amlodipine. In these two groups, 591 (0.6%) and 1185 (0.6%) of patients were hospitalised for bowel obstruction, respectively. We found no difference in the risk of bowel obstruction among patients treated with extended-release nifedipine compared with amlodipine (HR 1.09, 95% CI 0.96 to 1.24).
CONCLUSIONS: Bowel obstruction during treatment with extended-release nidefipine is rare, and the risk is not appreciably greater than that during treatment with amlodipine.
DESIGN: Retrospective cohort study using multiple linked healthcare databases.
SETTING: Ontario, Canada from 1 April 1997 to 31 December 2010.
PARTICIPANTS: We identified patients aged 66 years and older who started treatment with Adalat XL, an extended-release nifedipine product employing a tablet delivery system associated with mechanical bowel obstruction. For comparison, we studied patients receiving amlodipine, a long-acting calcium channel blocker that does not utilise the same delivery system and has not been implicated as a cause of bowel obstruction. Propensity score matching was used to ensure similarity of patients receiving the two drugs.
PRIMARY OUTCOME MEASURE: HR for the association between extended-release nifedipine relative to amlodipine and hospitalisation for bowel obstruction during therapy.
RESULTS: Over the 13-year study period, we identified 103 657 patients treated with extended-release nifedipine and 204 733 patients treated with amlodipine. In these two groups, 591 (0.6%) and 1185 (0.6%) of patients were hospitalised for bowel obstruction, respectively. We found no difference in the risk of bowel obstruction among patients treated with extended-release nifedipine compared with amlodipine (HR 1.09, 95% CI 0.96 to 1.24).
CONCLUSIONS: Bowel obstruction during treatment with extended-release nidefipine is rare, and the risk is not appreciably greater than that during treatment with amlodipine.